Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Resverlogix Secures an Additional $30 Million from Citibank Loan

Published: Saturday, July 05, 2014
Last Updated: Saturday, July 05, 2014
Bookmark and Share
Special meeting of shareholders called to approve.

Resverlogix Corp. has announced that it has entered into an Amended and Restated Loan Agreement with Citibank, N.A. ("Citibank") which provides for the existing loan granted to Resverlogix by Citibank to be increased by $30 million to $68.8 million (the "Amendment").

The loan will be repayable upon maturity on August 28, 2017 and may be prepaid in whole or in part without penalty. Interest on the loan will be payable annually in arrears at a rate equal to the per annum Canadian one-year LIBOR swap rate plus 3.14%, to be reset annually. The loan will be secured by an irrevocable $68.8 million Standby Letter of Credit (the "Letter of Credit") arranged by Eastern Capital Limited ("Eastern") which will be maintained until maturity of the loan.

Resverlogix intends to use the net proceeds from the loan to fund clinical trials in targeted high risk patient groups as well as research and development activities, general and administrative expenses and other general corporate purposes. The transaction was unanimously approved by Resverlogix's board of directors.

In connection with the Letter of Credit, Resverlogix has agreed to indemnify Eastern for all liabilities, costs and expenses arising from any payments made to Citibank under the Letter of Credit and, as with the previous Citibank loans, Resverlogix will pledge its patents and certain tax losses and pools to Eastern as security for its obligations under the indemnity.

Resverlogix will also issue an additional 5,000,000 share purchase warrants to Eastern in connection with the loan increase and will pay a guarantee fee to Eastern in the amount of 0.03% per annum on the average daily aggregate principal amount of the issued and undrawn Letter of Credit. Each warrant will be exercisable at $0.75 per share and will be exercisable for a period of five years. Eastern holds 14,965,307 shares of Resverlogix which represents 17.55% of the 85,289,247 common shares outstanding before giving effect to any outstanding warrants. Eastern currently holds 2,578,232 common share purchase warrants of Resverlogix.

Assuming all warrants are exercised before giving effect to the transaction, Eastern will hold approximately 19.97% of the common shares outstanding. After giving effect to the transaction, assuming all warrants held by Eastern are exercised, Eastern would hold 22,543,539 shares of Resverlogix representing 24.27% of Resverlogix's issued and outstanding common shares based on shares outstanding as at today's date.

The closing of the Amendment will be subject to, among other things, customary closing conditions for a transaction of this nature and shareholder approval of the majority of the votes cast by the shareholders of Resverlogix, excluding Eastern, at a special meeting of the shareholders of Resverlogix to be held on August 13, 2014 (the "Meeting"). A management information circular containing a complete description of the Amendment will be sent to shareholders in advance of the Meeting. The Amendment is scheduled to close in August 2014, subject to satisfaction of customary closing conditions and all necessary approvals being obtained. The issuance of the 5,000,000 share purchase warrants to Eastern is also subject to approval by the Toronto Stock Exchange.

"We are pleased to have the opportunity to further use our arrangement with Citibank and Eastern to fund our Phase 2b trial with considerably less dilution than conventional equity financing and with the flexibility to repay the loan in whole or in part at any time," stated Donald McCaffrey, President and CEO of Resverlogix. "We are looking forward to initiating our new RVX-208 clinical trials that will be based on the enormous epigenetic-related data that was generated in the exploratory ASSURE and SUSTAIN trials. RVX-208 has a very bright future in many indications ranging from arterial plaque regression to inflammatory diseases and various metabolic disorders." added Mr. McCaffrey.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Resverlogix Presents New Data at the ESC Congress 2015
Company presents new data on RVX-208 "apabetalone" a selective BET inhibitor.
Tuesday, September 01, 2015
International Clinical Steering Committee Announced from Resverlogix
Professor Kausik Ray to chair clinical steering committee for landmark epigenetic BET inhibition trial.
Saturday, August 08, 2015
Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority
Company expects to launch the upcoming BETonMACE Phase 3 clinical trial.
Tuesday, June 23, 2015
Resverlogix Presents New Data at 52nd Annual ERA-EDTA Congress
RVX-208, the first selective bromodomain extra-terminal (BET) protein inhibitor, significantly reduces alkaline phosphatase (ALP) levels in patients with high vascular risk.
Thursday, June 04, 2015
Resverlogix and Hepalink Announce a Combination Licensing and Equity Arrangement
The deal structure involves CAD$50 million in equity investments, and future China sales milestones and licensing royalties that could represent in excess of US$400 million.
Thursday, May 07, 2015
Resverlogix Presents at Biotech Showcase During JP Morgan Week
Donald McCaffrey share developments of the Company's proposed new phase 3 clinical trial BETONMACE.
Thursday, January 15, 2015
Resverlogix Appoints Senior Vice President of Clinical Development
Appointment of Michael T. Sweeney, M.D., as senior vice president.
Tuesday, November 04, 2014
RVX-208 Reduces MACE Significantly in Patients with Diabetes Mellitus
In addition, preliminary results from an Australian sponsored trial have yet to verify whether the mechanism of RVX-208 action may affect glucose metabolism.
Thursday, July 24, 2014
Resverlogix Granted European Patent
European Patent office grants RVX-208 patent until 2027.
Tuesday, March 18, 2014
Resverlogix Announces Two New Findings from the Phase 2b ASSURE Trial
RVX-208 lowers inflammation and MACE events while regressing atheroma in high risk CVD patients.
Monday, November 11, 2013
Resverlogix Completes Dosing in ASSURE Clinical Trial
IVUS data will evaluate plaque regression in patients with high-risk cardiovascular disease.
Friday, September 06, 2013
Resverlogix Reports Top-Line Results from ASSURE Clinical Trial
Company’s Phase 2b clinical trial evaluating RVX-208 did not meet its primary endpoint.
Friday, June 28, 2013
Resverlogix Establishes Clinical & Scientific Advisory Board
Dr. Bengt Winblad appointed Chairman of the clinical & scientific advisory board.
Wednesday, December 26, 2012
Resverlogix Initiates Phase 2 Clinical Trial of RVX-208
Data expected in the first half of 2014.
Friday, October 19, 2012
Resverlogix Completes Enrollment in ASSURE Trial
IVUS data will evaluate plaque regression in patients with coronary artery disease.
Monday, October 01, 2012
Scientific News
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Promising Drug for Parkinson's Disease
A drug which has already been in use for decades to treat liver disease could be an effective treatment to slow down progression of Parkinson’s disease, scientists from the University of Sheffield have discovered.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!